Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Yahoo! Finance
for the treatment of indolent systemic mastocytosis (ISM). AYVAKIT is approved by the U.S. Food and Drug Administration (FDA) for the treatment of three indications: adults with ISM, adults with advanced SM, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation. (Source: 'About AYVAKIT (avapritinib)' section) The data presentations highlight the survival benefits of front-line AYVAKIT use in patients with advanced SM, and support Blueprint Medicines' plans to evaluate novel clinical measures indicative of disease modification – such as bone density and biomarkers of chronic inflammation – in the registrational HARBOR trial. (Source: 'Data reported at ASH highlight the survival benefits of front-line AYVAKIT use in patients with advanced SM...' section) Ultra-sensitive KIT testing in the peripheral blood identified previously undetected KIT mutations in a number of PIONEER trial patients, suggesting that SM may be more
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.MarketBeat
- Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.MarketBeat
BPMC
Earnings
- 10/30/24 - Beat
BPMC
Sec Filings
- 12/20/24 - Form 4
- 12/20/24 - Form 4
- 12/19/24 - Form 144
- BPMC's page on the SEC website